search
Back to results

IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Primary Purpose

Solid Tumors

Status
Recruiting
Phase
Phase 1
Locations
Australia
Study Type
Interventional
Intervention
IBI334 D
IBI334 C
IBI334 A
IBI334 B
IBI334 F
IBI334 E
Sponsored by
Innovent Biologics (Suzhou) Co. Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Solid Tumors

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or female subjects ≥ 18 years old; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; Anticipated life expectancy of ≥ 12 weeks; Adequate bone marrow and organ function; Criteria for dose escalation phase only: Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available (mainly focused on non-small-cell lung cancer, head and neck squamous cell carcinoma and RAS-wildtype colorectal cancer); At least 1 evaluable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; Criteria for dose expansion phase only: Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic non-small-cell lung cancer, head and neck squamous cell carcinoma or RAS-wildtype colorectal cancer that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Exclusion Criteria: Participate in any other interventional clinical research except observational (non-interventional) study or in the follow-up phase of the interventional study; Received live vaccines within 4 weeks prior to first dose of the study drug or plan on receiving any live vaccine during the study; Received total pelvic radiotherapy; Pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours); Uncontrolled diseases; History of endotracheal or gastrointestinal stent implantation; Multiple concurrent malignant tumors within 5 years (except non-melanoma skin cancer, carcinoma in situ or non-invasive tumor that were cured); Women who are pregnant, have positive results in pregnancy test or are lactating; Not eligible to participate in this study at the discretion of the investigator.

Sites / Locations

  • Westmead HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

IBI334 E

IBI334 D

IBI334 C

IBI334 A

IBI334 F

IBI334 B

Arm Description

Outcomes

Primary Outcome Measures

Number of patients with treatment-related adverse events
Number of patients who experenced a treatment realted AEs from the first dose until 60 days after the last dose
Percentage of subjects woth Dose-Limitine toxicities(DLTs)
To evaluate the safety and tolerability of IBI334

Secondary Outcome Measures

Objective Response Rate (ORR)
Objective Response Rate (ORR) is the percentage of Complete Response (CR) plus partial response(PR) assessed per RECIST v1.1 criteria .
Duration of response (DoR)
For subjects with CR or PR, duration of response(DoR) is the time from the first documented CR or PR to diserse progression or death assessed per RECIST V1.1 criteria.
Disease control rate (DCR)
Disease control rate (DCR) is the percentage of CR plus PR Plus stable diserse (SD) assessed per RECIST v1.1 criteria.
Time to Response (TTR)
For subjects with CR or PR, time to response(TTR) is the time from first dose of study drugs to the first documented CR or PR assessed per RECIST v1.1 criteria.
Progression-free survival (PFS)
Time from randomization to first documented diserse progression (radiographic) assessed by investigator per RECIST v1.1 criteria or death due to any cause.
Overall survival (OS)
Time from randomization to death of the subject due to any cause.

Full Information

First Posted
February 8, 2023
Last Updated
October 20, 2023
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05774873
Brief Title
IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Official Title
A Phase 1 Study of IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 9, 2023 (Actual)
Primary Completion Date
October 31, 2025 (Anticipated)
Study Completion Date
June 30, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Innovent Biologics (Suzhou) Co. Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of this study to evaluate the safety and tolerability of IBI334 and determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI334.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
128 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
IBI334 E
Arm Type
Experimental
Arm Title
IBI334 D
Arm Type
Experimental
Arm Title
IBI334 C
Arm Type
Experimental
Arm Title
IBI334 A
Arm Type
Experimental
Arm Title
IBI334 F
Arm Type
Experimental
Arm Title
IBI334 B
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
IBI334 D
Intervention Description
Subjects will receive IBI334 D once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Intervention Type
Drug
Intervention Name(s)
IBI334 C
Intervention Description
Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Intervention Type
Drug
Intervention Name(s)
IBI334 A
Intervention Description
Subjects will receive IBI334 A once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Intervention Type
Drug
Intervention Name(s)
IBI334 B
Intervention Description
Subjects will receive IBI334 B once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Intervention Type
Drug
Intervention Name(s)
IBI334 F
Intervention Description
Subjects will receive IBI334 F once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Intervention Type
Drug
Intervention Name(s)
IBI334 E
Intervention Description
Subjects will receive IBI334 C once a week during the first 28-day cycle (QW, 4 weeks), then biweekly (or other dose intervals recommended by the Investigator and Sponsor based on safety, toxicity and PK data), until disease progression, toxicity intolerance, withdrawal of consent, occurrence of other reasons for discontinuing study therapy, or treatment duration reaches 24 months, whichever occurs first.
Primary Outcome Measure Information:
Title
Number of patients with treatment-related adverse events
Description
Number of patients who experenced a treatment realted AEs from the first dose until 60 days after the last dose
Time Frame
Up to 60 days post last dose
Title
Percentage of subjects woth Dose-Limitine toxicities(DLTs)
Description
To evaluate the safety and tolerability of IBI334
Time Frame
Up to 28 days following first dose
Secondary Outcome Measure Information:
Title
Objective Response Rate (ORR)
Description
Objective Response Rate (ORR) is the percentage of Complete Response (CR) plus partial response(PR) assessed per RECIST v1.1 criteria .
Time Frame
Up to 60 days post last dose
Title
Duration of response (DoR)
Description
For subjects with CR or PR, duration of response(DoR) is the time from the first documented CR or PR to diserse progression or death assessed per RECIST V1.1 criteria.
Time Frame
Up to 60 days post last dose
Title
Disease control rate (DCR)
Description
Disease control rate (DCR) is the percentage of CR plus PR Plus stable diserse (SD) assessed per RECIST v1.1 criteria.
Time Frame
Up to 60 days post last dose
Title
Time to Response (TTR)
Description
For subjects with CR or PR, time to response(TTR) is the time from first dose of study drugs to the first documented CR or PR assessed per RECIST v1.1 criteria.
Time Frame
Up to 60 days post last dose
Title
Progression-free survival (PFS)
Description
Time from randomization to first documented diserse progression (radiographic) assessed by investigator per RECIST v1.1 criteria or death due to any cause.
Time Frame
Up to 60 days post last dose
Title
Overall survival (OS)
Description
Time from randomization to death of the subject due to any cause.
Time Frame
Up to 60 days post last dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female subjects ≥ 18 years old; Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1; Anticipated life expectancy of ≥ 12 weeks; Adequate bone marrow and organ function; Criteria for dose escalation phase only: Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available (mainly focused on non-small-cell lung cancer, head and neck squamous cell carcinoma and RAS-wildtype colorectal cancer); At least 1 evaluable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; Criteria for dose expansion phase only: Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic non-small-cell lung cancer, head and neck squamous cell carcinoma or RAS-wildtype colorectal cancer that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Exclusion Criteria: Participate in any other interventional clinical research except observational (non-interventional) study or in the follow-up phase of the interventional study; Received live vaccines within 4 weeks prior to first dose of the study drug or plan on receiving any live vaccine during the study; Received total pelvic radiotherapy; Pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours); Uncontrolled diseases; History of endotracheal or gastrointestinal stent implantation; Multiple concurrent malignant tumors within 5 years (except non-melanoma skin cancer, carcinoma in situ or non-invasive tumor that were cured); Women who are pregnant, have positive results in pregnancy test or are lactating; Not eligible to participate in this study at the discretion of the investigator.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Emilia Tan
Phone
0512-69566088
Email
lili.tan@innoventbio.com
Facility Information:
Facility Name
Westmead Hospital
City
Waratah
State/Province
New South Wales
ZIP/Postal Code
2145
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adnan Nagrial
Phone
02 8890 5200
Email
adnan.nagrial@health.nsw.gov.au
First Name & Middle Initial & Last Name & Degree
Adnan Nagrial, M.D.
First Name & Middle Initial & Last Name & Degree
Lisi Elizabeth Lim, M.D.

12. IPD Sharing Statement

Learn more about this trial

IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

We'll reach out to this number within 24 hrs